Home > Insider Trading > Filing (0001104659-13-023061)

Filing Details

Accession Number:: 0001104659-13-023061
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-03-21 22:54:17
Reporting Period:: 2013-03-11

Filing Date:: 2013-03-21
Accepted Time:: 2013-03-21 21:54:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1511472	Andreas Wicki	Centennial Towers, 3Rd Floor 2454 West Bay Road Grand Cayman E9		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-03-11	500,000	$27.86	2,933,993	No	4	S	Indirect	See footnote
Common Stock	Disposition	2013-03-18	400,000	$28.19	2,533,993	No	4	S	Indirect	See footnote
Common Stock	Disposition	2013-03-19	9,100	$27.86	2,524,893	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,433,993	Indirect	See footnote

Footnotes

This number reflects the correction of the total holdings of the reporting person which was incorrectly reported on the reporting person's original Form 3 and two subsequent Form 4 filings.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HBM Healthcare Investments (Cayman) Ltd., formerly known as HBM BioVentures (Cayman) Ltd. ("HBM'), on March 15, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.775 to $28.75 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.
These securities are held by HBM. The board of directors of HBM (the "HBM Board") has sole voting and investment power with respect to the securities held by such entity and acts by majority vote. The reporting person does not have sole voting or investment power over the securities held by HBM. However, the reporting person may be deemed to have beneficial ownership of these securities by virtue of his membership on the Board of HBM. The reporting person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.11 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote five (5) of this Form 4.